Home  | Publications | SWM+26

Clinical Outcome and Cost Analyses in Adult Patients With Acquired Hemophilia A- A Single Center, Retrospective Analysis

MCML Authors

Abstract

Introduction: Acquired hemophilia A (AHA) is a rare, potentially life-threatening bleeding disorder (incidence ~1 per million) caused by autoantibody-mediated neutralization of coagulation factor VIII (FVIII). The resulting loss of FVIII activity markedly impairs thrombin generation and fibrin formation, leading to spontaneous or disproportionate soft-tissue and muscular bleeding. AHA often occurs in association with malignancy, autoimmune disease, or the postpartum period. However, comprehensive real-world data on outcomes, prognostic factors, and the economic burden of AHA management remain limited.<br>Method: We retrospectively analyzed 51 adults newly diagnosed with AHA at University Hospital LMU Munich (2011–2023). Diagnosis required clinically relevant bleeding, detectable FVIII inhibitors (Bethesda units, BU), and FVIII activity<50%. Bleeding severity was classified according to EACH2 criteria. We evaluated 100-day survival, remission, complications, and in-hospital medication costs. Survival was analyzed using Kaplan–Meier and Cox proportional hazards models.<br>Results: Median age was 76 years (range 33–90), 49% were male, and median Charlson Comorbidity Index was 4. Etiology was idiopathic in 59%, autoimmune-related in 27%, malignancy-associated in 8%, and postpartum in 6%. Soft-tissue and muscular bleeding predominated; 64% experienced severe bleeding during hospitalization [1] [2].

article SWM+26

Hamostaseologie

46.S 01. Feb. 2026.

Authors

A. Seidl • T. Weiglein • P. Möhnle • L. H. Lindner • K. Berger • M. A. Antabi • R. Rehms • M. von Bergwelt • K. Spiekermann

Links

DOI

Research Area

 C1 | Medicine

BibTeXKey: SWM+26

#p-rueckert
Back to Top